Partnering for Impact: Open Dialogue, Strategic Growth

Inorganic metal nanoparticles are increasingly utilized in tissue engineering and biomedical applications due to their intrinsic biocompatibility, low cytotoxicity, and biodegradability. At the nanoscale, precise manipulation of material properties enables the fabrication of structures with enhanced functional performance across a broad array of biomedical domains—including controlled drug delivery, biomarker detection, molecular sensing, targeted therapeutics, advanced imaging modalities, biosensing platforms, and regenerative tissue scaffolds.

Nanomaterials exhibit unique physicochemical characteristics driven by their high surface-to-volume ratios, which promote cellular nutrient exchange, enhance tissue viability, and support three-dimensional matrix formation conducive to cell adhesion, differentiation, and neotissue development. Architectures incorporating nanofibers, nanoparticles, and nanocomposites can emulate the extracellular matrix, facilitating vascularization and the engineering of artificial blood vessels.

Surface functionalization of nanoparticles significantly improves targeting specificity, enabling encapsulation and directed delivery of bioactive agents—such as drugs, vitamins, and therapeutic compounds—while preserving molecular integrity. These modifications enhance treatment efficacy and reduce systemic side effects. Moreover, nanometric coatings improve material biocompatibility, stimulate cellular adhesion, inhibit microbial colonization, and modulate immunological responses, thereby extending the functional lifespan of biomedical implants, including orthopedic devices, cardiovascular stents, and dental prosthetics.

TENGENA is actively advancing its nanoplatform to support emerging applications in nanoelectronics, catalysis, magnetic data storage, structural reinforcement, biomaterials, and biosensing. Utilizing sub-2 nm metal nanoparticles and nanometric constructs efficiently immobilized on nitrocellulose substrates, our platform enhances imaging sensitivity, resolution, and detectability across modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and fluorescence imaging—enabling early disease detection and real-time physiological monitoring. Additionally, our proprietary fabrication technologies support the development of ultra-sensitive nanosensors and nanoprobes for biomarker detection, significantly expanding the diagnostic landscape.

The strategic engineering of nanomaterials has revolutionized pharmaceutical and biotechnological platforms by overcoming the limitations of free-form therapeutics and navigating complex biological barriers—systemic, microenvironmental, and intracellular. Nanoparticles (NPs), with their quantized electronic energy levels and quantum confinement effects, exhibit distinct physical and chemical properties compared to bulk materials. These include tunable size, surface area, and electron delocalization, which directly influence reactivity, conductivity, fluorescence, and magnetic permeability.

Functionalization at atomic, molecular, and supramolecular levels enables precise modulation of these properties, allowing nanomaterials to enhance composite systems or serve as standalone components in advanced therapeutic devices. Lipid-based, polymeric, and inorganic nanoparticles are increasingly tailored for precision medicine, supporting controlled release, targeted biodistribution, and bioresponsive behavior. Recent synthesis strategies incorporate complex architectures and targeting moieties to overcome heterogeneous biological barriers and improve therapeutic efficacy.

Among the most impactful diagnostic tools enabled by nanotechnology are lateral flow assays (LFAs)—rapid, point-of-care platforms that utilize nanoparticle-labeled probes for the detection of biomarkers, pathogens, and analytes. LFAs have evolved from qualitative strip tests to highly sensitive, multiplexed systems capable of quantitative analysis. Applications span infectious disease surveillance, cancer screening via liquid biopsy, cardiovascular monitoring, and environmental toxin detection. Nanoparticle-enhanced LFAs, particularly those using gold, magnetic, or quantum dot labels, offer improved signal clarity, lower limits of detection, and compatibility with AI-based interpretation algorithms.

TENGENA is actively optimizing its nanoplatforms to support these diagnostic innovations. By designing sub-2 nm metal nanoparticles and nanometric constructs immobilized on nitrocellulose substrates, our systems enhance imaging resolution and biosensor sensitivity across modalities such as MRI, CT, and fluorescence imaging. These platforms also enable the development of ultra-specific nanosensors and nanoprobes for biomarker detection—expanding the diagnostic landscape and supporting real-time physiological monitoring.